Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma (October 2020)

Monday, October 19, 2020
Webinar -- 1:30 PM CET
https://www.clinicaloptions.com/ESMO2020HCCJoin1

Agenda

Brief Overview of Immuno-Oncology in HCC
Bruno Sangro, MD, PhD

Immunotherapy Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials
Ghassan Abou-Alfa, MD

Immunotherapy Combinations in Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
Peter Galle, MD, PhD

Putting It All Together: Case Discussions
Panel Discussion

Final Thoughts and Audience Question and Answer Session

Faculty

Program Chair
Ghassan Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty
Peter Galle, Other

Chairman
First Department of Internal Medicine
University Medical Center
Mainz, Germany

Faculty
Bruno Sangro, MD, PhD

Professor of Medicine
Head

Liver Unit and HPB Oncology Area
Universidad de Navarra
Pamplona, Spain

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners to integrate currently available and emerging immune checkpoint inhibitor–based therapies for treatment of HCC.

Target Audience
This program is intended for global medical oncologists, hepatologists, and other healthcare providers who care for patients with HCC.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify patients with HCC most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Evaluate clinical data on the use of immune checkpoint inhibitor–based treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitor therapy in patients with HCC

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.